http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 08:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jul+27/26816448.html si-local-file:///var/storage/secattach/20260727/26816448.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jul+27/26816448.html Mon, 27 Jul 2026 08:05:00 -0400 O.37894223 SPRB SPRBD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jul+27/26816448.html si-local-file:///var/storage/secattach/20260727/26816448.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jul+27/26816448.html Mon, 27 Jul 2026 08:05:00 -0400 O.37894223 SPRB SPRBD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jul+27/26816448.html si-local-file:///var/storage/secattach/20260727/26816448.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SPRUCE+BIOSCIENCES%2C+INC.++For%3A+Jul+27/26816448.html Mon, 27 Jul 2026 08:05:00 -0400 O.37894223 SPRB SPRBD http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html <p>Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, the South San Francisco-based biopharmaceutical company announced.</p> <p>Dr. Quartel joins from Zevra Therapeutics, where he served as chief medical officer. He previously held the same role at Acer Therapeutics and Adamas Pharmaceuticals. Earlier in his career, as group vice president of global medical affairs at BioMarin Pharmaceutical, he led the launch of six treatments for rare diseases, including the enzyme replacement therapies Naglazyme, Vimizim, and Brineura. He also held senior positions at Astellas, Chiltern, and ICON Clinical Research.</p> <p>Dr. Quartel holds an M.D. from Erasmus University Medical School http://www.streetinsider.com/Management+Changes/Spruce+Biosciences+names+Adrian+Quartel+as+chief+medical+officer/26816291.html Mon, 27 Jul 2026 08:00:19 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html <p class="bwalignc"><i>Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders</i></p> <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior http://www.streetinsider.com/Press+Releases/Spruce+Biosciences+Appoints+Adrian+Quartel%2C+M.D.%2C+FFPM%2C+as+Chief+Medical+Officer/26816246.html Mon, 27 Jul 2026 08:00:00 -0400 A.25838468 A.27085589 A.50113770 A.50114026 A.50201488 O.01129312 O.02506235 O.08429242 O.12396261 O.37894223 O.41110522 SPRB